Cargando…

Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients

A fraction of patients with COVID-19 develops severe disease requiring hospitalization, while the majority, including high-risk individuals, experience mild symptoms. Severe disease has been associated with higher levels of antibodies and inflammatory cytokines but often among patients with diverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klingler, Jéromine, Lambert, Gregory S., Bandres, Juan C., Emami-Gorizi, Rozita, Nádas, Arthur, Oguntuyo, Kasopefoluwa Y., Amanat, Fatima, Bermúdez-González, Maria C., Gleason, Charles, Kleiner, Giulio, Simon, Viviana, Lee, Benhur, Zolla-Pazner, Susan, Upadhyay, Chitra, Hioe, Catarina E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666267/ https://www.ncbi.nlm.nih.gov/pubmed/36406863 http://dx.doi.org/10.1016/j.isci.2022.105608

Ejemplares similares

Detection of Antibody Responses against SARS-CoV-2 in Plasma and Saliva from Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals
por: Klingler, Jéromine, et al.
Publicado: (2021)

Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

The IgA in milk induced by SARS-CoV-2 infection is comprised of mainly secretory antibody that is neutralizing and highly durable over time
por: Fox, Alisa, et al.
Publicado: (2022)

A HIGH THROUGH-PUT ASSAY FOR CIRCULATING ANTIBODIES DIRECTED AGAINST THE S PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
por: Weiss, Svenja, et al.
Publicado: (2020)

A High-Throughput Assay for Circulating Antibodies Directed Against the S Protein of Severe Acute Respiratory Syndrome Coronavirus 2
por: Weiss, Svenja, et al.
Publicado: (2020)

Alterations of HIV-1 envelope phenotype and antibody-mediated neutralization by signal peptide mutations
por: Upadhyay, Chitra, et al.
Publicado: (2018)

Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies
por: Shen, Guomiao, et al.
Publicado: (2015)

Proteases and variants: context matters for SARS-CoV-2 entry assays
por: Stevens, Christian S, et al.
Publicado: (2021)

Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes
por: Upadhyay, Chitra, et al.
Publicado: (2020)

Quantifying absolute neutralization titers against SARS-CoV-2 by a standardized virus neutralization assay allows for cross-cohort comparisons of COVID-19 sera
por: Oguntuyo, Kasopefoluwa Y., et al.
Publicado: (2020)

Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
por: Oguntuyo, Kasopefoluwa Y., et al.
Publicado: (2021)

Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity
por: Mayr, Luzia M., et al.
Publicado: (2017)

Indirect Detection of an Epitope-Specific Response to HIV-1 gp120 Immunization in Human Subjects
por: Shmelkov, Evgeny, et al.
Publicado: (2011)

HIV-1 Envelope Glycan Composition as a Key Determinant of Efficient Virus Transmission via DC-SIGN and Resistance to Inhibitory Lectins
por: Jan, Muzafar, et al.
Publicado: (2019)

Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice
por: Hioe, Catarina E., et al.
Publicado: (2022)

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
por: Balasubramanian, Preetha, et al.
Publicado: (2018)

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
por: Chiu, Y, et al.
Publicado: (2012)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Crystal structure and solution state of the C-terminal head region of the narmovirus receptor binding protein
por: Stelfox, Alice J., et al.
Publicado: (2023)

Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
por: Hioe, Catarina E., et al.
Publicado: (2018)

Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing
por: Park, Arnold, et al.
Publicado: (2016)

Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes
por: Hioe, Catarina E., et al.
Publicado: (2010)

Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Heterogeneity in glycan composition on the surface of HIV-1 envelope determines virus sensitivity to lectins
por: Jan, Muzafar, et al.
Publicado: (2018)

Identifying epitopes of HIV-1 that induce protective antibodies
por: Zolla-Pazner, Susan
Publicado: (2004)

Robust and Specific Secretory IgA Against SARS-CoV-2 Detected in Human Milk
por: Fox, Alisa, et al.
Publicado: (2020)

A Rare Case of Schwann Cell Hamartoma in the Duodenum
por: Oguntuyo, Kasopefoluwa Y., et al.
Publicado: (2022)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

Immunoprophylaxis against Mother-to-Child Transmission of HIV-1
por: Gorny, Miroslaw K, et al.
Publicado: (2006)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
por: Swetnam, J, et al.
Publicado: (2009)

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
por: Ikegame, Satoshi, et al.
Publicado: (2021)

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
por: Ikegame, Satoshi, et al.
Publicado: (2021)

On the Need to Distinguish between Insulin-Normal and Insulin-Resistant Patients in Testosterone Therapy
por: Zolla, Lello
Publicado: (2022)

Different Pattern of Immunoglobulin Gene Usage by HIV-1 Compared to Non-HIV-1 Antibodies Derived from the Same Infected Subject
por: Li, Liuzhe, et al.
Publicado: (2012)

Residue 315 regulates V3 exposure and V3 antibody recognition on HIV subtype B and C viruses
por: Manhas, S, et al.
Publicado: (2012)

Comparative Magnitude of Cross-Strain Conservation of HIV Variable Loop Neutralization Epitopes
por: Swetnam, James, et al.
Publicado: (2010)

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
por: Ikegame, Satoshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fje1t7io44dvv69b0lgg4gbb7q